EUCTR2013-000867-10-GB进行中（未招募）1 期
Effects of Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction (HF-PEF): Cardiac MRI, Echocardiography, Exercise Physiology & Quality of Life Assessment - Cardiac MRI in HF-PEF
niversity of Leeds0 个研究点目标入组 51 人开始时间: 2014年2月13日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 51
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Diagnosis of heart failure with preserved ejection fraction (HF-PEF)
- •NYHA II-IV heart failure
- •Compliance with medical treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Contra-indication to undergoing full cardiac magnetic resonance study
- •Contra-indication to aldosterone antagonist therapy
- •Contra-indication to exercise testing
- •Unable to give informed consent
研究者
相似试验
尚未招募
4 期
se of aldosterone blockade to improve cardiac function in obesityDiastolic DysfunctionMyocardial fibrosisCardiovascular - Other cardiovascular diseasesACTRN12609000655246The University of Queensland120
Unknown
早期 1 期
Non Invasive Assessment of Heart FailureHeart FailureNCT04078425Assiut University100
已完成
3 期
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic FunctionCardiovascular DiseasesHeart DiseasesHeart Failure, CongestiveNCT00094302Carelon Research3,445
已完成
4 期
Aldosterone Antagonism in Diastolic Heart FailureDiastoleCongestive Heart FailureNCT00108251US Department of Veterans Affairs48
进行中（未招募）
不适用
Establishing the benefits of a tablet commonly used to treat raised blood pressure in people with Chronic Kidney Disease stage 3b.We plan a large pragmatic trial to test the potential for spironolactone to to reduce overall cardiovascular events and death, to delay the decline in renal function, and to improve surrogate markers for vascular disease in people with stage 3b (eGFR 30-44 ml/min/1.73m2)Chronic Kidney Disease.MedDRA version: 15.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 15.1Level: PTClassification code 10018355Term: Glomerular filtration rateSystem Organ Class: 10022891 - InvestigationsMedDRA version: 15.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2012-002672-13-GBniversity of Oxford, Clinical Trials and Research Governance Office2,616